ArticleRadiation oncology (London, England)2022
Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?
Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Postsurgical outcomes of nonfunctioning pituitary adenomas: a patient-level meta-analysis.Pituitary · 2023Pooled it
- Clinician decision-making in non-functioning pituitary adenomas: an Australian and New Zealand interdisciplinary survey study.Pituitary · 2026Article
- Radiotherapy regimens and concurrent Cabergoline use for non-functioning pituitary neuroendocrine tumors: a large, single-center cohort.Endocrine · 2026Article
- Clinical, radiological, and pathological characteristics and long-term outcomes of silent corticotroph adenomas: a retrospective study.BMC endocrine disorders · 2025Article
- Pituitary adenoma extended to the basilar sinus: Lessons from anatomical and radiological studies (Experimental Research).Neurosurgical review · 2025Article
- Article
- Comprehensive Fertility Management After Pituitary Adenoma Surgery: Lessons from a Rural Japanese Case and Practical Review.Reports (MDPI) · 2025Article
- The Evolution of Pituitary Surgery in an Australian Health Care Framework.Journal of neurological surgery. Part B, Skull base · 2025Article
- Brain radiotherapy and dorsal vagal complex irradiation: A new organ at risk to decrease radiation-induced nausea and vomiting?Clinical and translational radiation oncology · 2025Article
- Pituitary Macroadenoma and Adamantinomatous Craniopharyngioma: A Rare Case Report of Sellar Collision Tumors.Case reports in neurological medicine · 2025Article
- Comparative analysis of the effects of microscopic vs. neuroendoscopic transsphenoidal surgery on visual and pituitary function and postoperative recurrence factors in patients with pituitary tumors.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe first line of treatment for nonfunctioning pituitary adenoma (NFPA) is surgery. Adjuvant radiotherapy or surveillance and new treatment (second surgical operation or salvage radiotherapy) in case of recurrence are options discussed at the multidisciplinary tumor board. The purpose of this study was to evaluate the therapeutic outcome for each option.
methodsThe records of 256 patients followed with NFPA between 2007 and 2018 were retrospectively reviewed. Mean age at initial surgery was 55 years [18-86]. Post-operative MRI found a residual tumor in 87% of patients. Mean follow-up was 12.1 years [0.8-42.7].
resultsAfter initial surgery, 40 patients had adjuvant radiotherapy. At 5, 10 and 15 years progression-free survival (PFS) was significantly different after surgery alone (77%, 58% and 40%) compared to surgery and adjuvant radiotherapy (84%, 78% and 78%) (HR = 0.24 [0-0.53] p < 0.0005). Overall, after first, second or third surgical operation, 69 patients had adjuvant radiotherapy and 41 salvage radiotherapy. Five-year PFS was similar for adjuvant (90%) and salvage radiotherapy (97%) (p = 0.62). After a second surgical operation, 62% and 71% of patients were irradiated after 2 and 5 years respectively. The risk of corticotropic and thyrotropic deficiency rates were 38% and 59% after second or third surgical operation and 40% and 73% after radiotherapy. Brain tumors occurred in 4 patients: 1 meningioma present at initial surgery, and after radiotherapy, 1 neurinoma which appeared at 5 years, 1 glioblastoma at 13 years and 1 meningioma at 20 years.
conclusionAmong patients treated by surgery for NFPA, a "wait-and-see" attitude should be an option since adjuvant radiotherapy is not superior to salvage radiotherapy. However, in case of recurrence or progression, the authors recommended delivery of salvage radiotherapy to avoid a second surgical operation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.